Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment (Q37862242)

24 August 2017

1 reference

title

Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment (English)

1 reference

24 August 2017

0 references

0 references

1

Gary Remington

1 reference

24 August 2017

2

Ofer Agid

1 reference

24 August 2017

3

George Foussias

1 reference

24 August 2017

1 April 2011

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

24 August 2017

1 reference

24 August 2017

11

1 reference

24 August 2017

4

1 reference

24 August 2017

589-607

1 reference

On the presence of 3-hydroxytyramine in brain.

24 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

The action of dopamine on the arterial blood pressure of the guinea-pig

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Dopamine miracle: from brain homogenate to dopamine replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Catechol compounds in rat tissues and in brains of different animals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Role of the dopaminergic system in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Dopamine receptors and the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

The history of dopamine and levodopa in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Dopamine: 50 years in perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Dopamine and the regulation of cognition and attention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Modulatory Actions of Neurotransmitters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Alterations of dopamine and serotonin transmission in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Widespread origin of the primate mesofrontal dopamine system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Opposite effects of neurotensin on dopamine inhibition in different regions of the rat brain: an iontophoretic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Extensive co-localization of neurotensin with dopamine in rat meso-cortico-frontal dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Parkinson's disease: a major hypokinetic basal ganglia disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Co-stimulation of D(1)/D(5) and D(2) dopamine receptors leads to an increase in c-fos messenger RNA in cholinergic interneurons and a redistribution of c-fos messenger RNA in striatal projection neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Prefrontal cortical D1 dopamine receptors modulate subcortical D2 dopamine receptor-mediated stress responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

The cerebral cortex: a case for a common site of action of antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

D1 and D4 dopaminergic receptor interplay mediates coincident G protein-independent and dependent regulation of glutamate NMDA receptors in the lateral amygdala

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Dopamine D1 receptor-mediated NMDA receptor insertion depends on Fyn but not Src kinase pathway in prefrontal cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Effects of asenapine on prefrontal N-methyl-D-aspartate receptor-mediated transmission: involvement of dopamine D1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Functional interaction between dopamine receptor subtypes for the regulation of c-fos expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Psychosis pathways converge via D2high dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Ex vivo [11C]-(+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Introduction: genes, cognition and neuropsychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Molecular mechanisms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Prefrontal cognitive systems in schizophrenia: towards human genetic brain mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

The dopamine hypothesis of schizophrenia: version III--the final common pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Antipsychotic drug doses and neuroleptic/dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Do we still believe in the dopamine hypothesis? New data bring new evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Elevation of prolactin levels by atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Prolactin and dopamine: what is the connection? A review article

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Dopamine D4 receptors and development of newer antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Update on dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Markers close to the dopamine D5 receptor gene (DRD5) show significant association with schizophrenia but not bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

The dopamine D4 receptors and mechanisms of antipsychotic atypicality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Defining treatment refractoriness in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Clozapine. A novel antipsychotic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

The history of clozapine and its emergence in the US market: a review and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

21 January 2018

The history of clozapine

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Negative v positive schizophrenia. Definition and validation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Progress in defining optimal treatment outcome in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Negative symptoms and cognitive deficits: what is the nature of their relationship?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

A separate disease within the syndrome of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Neuropsychiatric symptoms in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Apathy and depression in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

The syndromal validity and nosological position of apathy in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Apathy in drug-naïve patients with incident Parkinson's disease: the Norwegian ParkWest study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Disconnecting force from money: effects of basal ganglia damage on incentive motivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

The subthalamic nucleus is a key-structure of limbic basal ganglia functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Association of preoperative symptom profile with psychiatric symptoms following subthalamic nucleus stimulation in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Subjective response to antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Monoamine depletion in psychiatric and healthy populations: review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia--findings from an in vivo SPECT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Estimation of baseline dopamine D2 receptor occupancy in striatum and extrastriatal regions in humans with positron emission tomography with [18F] fallypride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Reward processing after catecholamine depletion in unmedicated, remitted subjects with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Cognitive-nigrostriatal relationships in de novo, drug-naïve Parkinson's disease patients: a [I-123]FP-CIT SPECT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Non-dopaminergic treatments in development for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Course of neurocognitive deficits in the prodrome and first episode of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

21 January 2018

Haloperidol in Normals

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Biomarkers for the effects of antipsychotic drugs in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Decreased binding of [11C]NNC112 and [11C]SCH23390 in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Antipsychotics and working memory in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Correlation between errors on the Wisconsin Card Sorting Test and the availability of striatal dopamine transporters in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Implications of normal brain development for the pathogenesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Neurodegeneration in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Is there a degenerative process going on in the brain of people with Schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Early cerebro-craniofacial dysmorphogenesis in schizophrenia: a lifetime trajectory model from neurodevelopmental basis to 'neuroprogressive' process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Neurodevelopmental and neuroprogressive processes in schizophrenia. Antithetical or complementary, over a lifetime trajectory of disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

The neurodevelopmental hypothesis of schizophrenia, revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

The prodromal phase of first-episode psychosis: past and current conceptualizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Recent advances in treating cognitive impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Negative symptoms of schizophrenia: a problem that will not go away

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Motivational deficits as the central link to functioning in schizophrenia: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Negative symptoms in schizophrenia: avolition and Occam's razor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Science and recovery in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Neurodevelopmental factors associated with schizotypal symptoms among adolescents at risk for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Early developmental milestones and risk of schizophrenia: a 45-year follow-up of the Copenhagen Perinatal Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Schizophrenia as dopamine-deficiency disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Catechol O-methyltransferase Val158Met polymorphism is associated with cognitive performance in nondemented adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Catechol-O-Methyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-affective psychosis: clinical-onset implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Review of Antipsychotic Medication Administration: A Proposal of Intermittent Dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Neuroleptic dysphoria: towards a new synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Cognition in young schizophrenia outpatients: comparison of first-episode with multiepisode patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Amphetamine sensitization alters dendritic morphology in prefrontal cortical pyramidal neurons in the non-human primate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Reversal of neuronal and cognitive consequences of amphetamine sensitization following chronic treatment with a D1 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Amphetamine sensitization impairs cognition and reduces dopamine turnover in primate prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Prenatal disruption of neocortical development alters prefrontal cortical neuron responses to dopamine in adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Presynaptic regulation of dopamine transmission in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Plasticity at hippocampal to prefrontal cortex synapses is impaired by loss of dopamine and stress: importance for psychiatric diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Dynamic changes in accumbens dopamine correlate with learning during intracranial self-stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Coordinated accumbal dopamine release and neural activity drive goal-directed behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Glycine transport inhibitors and the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Aripiprazole in schizophrenia and schizoaffective disorder: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Neurotransmitter interactions in schizophrenia--therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Schizophrenia: from dopamine to glutamate and back

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Dopaminergic enhancement of cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Selective dopamine D3 receptor antagonists: a review 2001-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

"Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Drugs in development for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Is active psychosis neurotoxic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Is early intervention in psychosis cost-effective over the long term?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Rapid response to antipsychotic treatment on psychotic prodrome: implications from a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Intervention in individuals at ultra-high risk for psychosis: a review and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Intervention in the at-risk state to prevent transition to psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Toward a better identification and treatment of schizophrenia prodrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Combination therapy in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Polypharmacy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Pharmacological approaches to the management of cognitive dysfunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Pharmacological cognitive enhancement in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

The endophenotype concept in psychiatry: etymology and strategic intentions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Schizophrenia endophenotypes as treatment targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

Selective Relationship Between PrefrontalN-Acetylaspartate Measures and Negative Symptoms in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.191

21 January 2018

Identifiers

DOI

10.1586/ERN.10.191

1 reference

24 August 2017

1 reference

PubMed ID

21469931